Clinical trial
Real World Effectiveness of Natalizumab Extended Interval Dosing in Relapsing-Remitting Multiple Sclerosis in a French Cohort
NCT04580381 is registered in ClinicalTrials.gov with University Hospital, Caen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real World Effectiveness of Natalizumab Extended Interval Dosing in Relapsing-Remitting Multiple Sclerosis in a French Cohort
- Lead sponsor
- University Hospital, Caen
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 1, 2020
- Completion date
- October 30, 2021
- Enrollment
- 500 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.